W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer…
Miasta: Białystok, Olsztyn, Poznań, Siedlce i 2 inne miastaWiek: od 18 latSponsor: Glaxosmithkline Research & Development Limited
RekrutujeObserwacyjne
Panuri Performance Study
Miasta: Dąbrowa Tarnowska, Gdańsk, Grudziądz, Iława i 12 innych miastWiek: od 18 latSponsor: Urteste S.A
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With…
Miasta: Białystok, Gdańsk, Gdynia, Poznań i 2 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Miasta: Białystok, Gliwice, Kielce, Kraków i 9 innych miastWiek: od 18 latSponsor: BioNTech SE
RekrutujeFaza III
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
Miasta: Białystok, Poznań, Siedlce, Szczecin i 1 inne miastoWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Miasta: Gdańsk, Gliwice, Lublin, Poznań i 2 inne miastaWiek: od 18 latSponsor: Janssen Cilag International
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive…
Miasta: Białystok, Gdańsk, Katowice, Lublin i 3 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Miasta: Białystok, Gdańsk, Kraków, Poznań i 1 inne miastoWiek: od 18 latSponsor: Eli Lilly & Co.
RekrutujeFaza III
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Miasta: Białystok, Kielce, Lublin, Poznań i 3 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Miasta: Gliwice, Koszalin, Poznań, Rzeszów i 1 inne miastoWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair…
Miasta: Białystok, Gdańsk, Gliwice, Kielce i 3 inne miastaWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer…
Miasta: Białystok, Bydgoszcz, Gdynia, Koszalin i 6 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
RekrutujeFaza III
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
Miasta: Poznań, Siedlce, SzczecinWiek: od 18 latSponsor: Daiichi Sankyo Inc.
RekrutujeFaza III
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive…
Miasta: Białystok, Konin, Koszalin, Kraków i 7 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Miasta: Bielsko-Biala, Koszalin, Poznań, WarszawaWiek: od 18 latSponsor: Daiichi Sankyo Inc.
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume…
Miasta: Gliwice, PoznańWiek: od 18 latSponsor: Centre Leon Berard
W Polsce: Wkrótce rekrutacjaNa świecie: RekrutujeFaza III
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
Miasta: Białystok, Gdańsk, Kraków, Poznań i 4 inne miastaWiek: od 18 latSponsor: Genmab A/S
RekrutujeFaza III
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Miasta: Białystok, Gdańsk, Gliwice, Kraków i 4 inne miastaWiek: od 0 latSponsor: AstraZeneca AB
RekrutujeFaza III
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive…
Miasta: Bydgoszcz, Gdańsk, Gdynia, Gliwice i 5 innych miastWiek: od 18 latSponsor: F. Hoffmann-La Roche AG
RekrutujeFaza III
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1…
Miasta: Biała Podlaska, Gliwice, Kraków, Poznań i 2 inne miastaWiek: od 18 latSponsor: Leonabio Inc.
RekrutujeFaza III
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
Miasta: Białystok, Grzepnica, Lublin, Olsztyn i 1 inne miastoWiek: od 18 latSponsor: AstraZeneca AB
W Polsce: ZakończoneNa świecie: RekrutujeFaza III
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Miasta: Bydgoszcz, Gdańsk, Poznań, WarszawaWiek: od 18 latSponsor: Astrazeneca AB
RekrutujeFaza III
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include…
Miasta: Białystok, Brzeziny, Bydgoszcz, Gdańsk i 11 innych miastWiek: od 18 latSponsor: Merck Sharp & Dohme LLC
Rekrutacja wkrótceFaza III
A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)
Miasta: Białystok, Gdańsk, Poznań, Siedlce i 2 inne miastaWiek: od 18 latSponsor: Daiichi Sankyo Inc.